Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The FDA approved Zepbound (tirzepatide for obesity) on November 8, 2023 [2], meaning it entered the obesity-specific reimbursement field only recently
These medications mimic a natural hormone to regulate appetite and promote fat loss
While some individuals have reported positive outcomes, including weight management and energy improvements, others might not experience the same level of benefits
The potential here looks very promising
In 2021, results from the STEP-1 trial were published
US$ 27.61
US$ 24.11
US$ 21.60
US$ 21.44
